CRYL1 and glioblastoma: The recent reports discussed in this review show that despite promising results with chronotherapy schedules on different types of cancer, further research is needed in the context of GBM to implement different delivery schemes based on circadian rhythms for new antitumor drugs such as REV-ERB and CRY agonists, together with or as an alternative to already approved TMZs, in order to improve the survival of patients diagnosed with this devastating disease.